ArticleAtherosclerosis plus2026
Real-world cardiovascular risk estimation, blood pressure and LDL-cholesterol control: Two epidemiological studies in Romania, during pandemic and post-pandemic (SNAPSHOT-Romania).
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Data on estimation of cardiovascular (CV) risk by physicians and perceptions of hypertension and dyslipidemia control are lacking in Eastern Europe. Therefore, in patients with hypertension and dyslipidemia, during the COVID-19 pandemic and post-pandemic periods, we compared CV risk, blood pressure (BP) and low-density lipoprotein-cholesterol (LDL-C) control, as assessed by physicians, with the recommendations of the European guidelines. Methods: Two observational, cross-sectional, epidemiological studies with similar designs were conducted in Romania during the pandemic (SNAPSHOT-1, June 2021) and post-pandemic (SNAPSHOT-2, June 2022). Results: We included 5004 patients with hypertension and dyslipidemia: 2469 in SNAPSHOT-1 and 2535 in SNAPSHOT-2. In SNAPSHOT-1, the CV risk estimated by investigators was "high" or "very high" for 34.3% and 35.4% of patients, respectively, whereas the CV risk based on guidelines recommendations was "high" or "very high" for 12.6% and 81.8% of patients; 41.5% of investigators estimated the CV risk accurately, whereas 54.2% underestimated it. BP and LDL-C were considered to be controlled by investigators in 71.2% and 46.1% of patients, respectively, whereas control rates based on guideline recommendations were achieved in 25.0% and 8.8% of patients. Both targets were considered controlled together by investigators in 39.6% of patients versus 3.3% based on guideline recommendations. The SNAPSHOT-2 results were similar. Conclusions: SNAPSHOT studies have shown that the estimation of CV risk by physicians is accurate in fewer than half of patients, being markedly underestimated. BP and LDL-C control is overestimated by physicians, whereas control rates, as recommended by the guidelines, are very low. The results were similar when a similar population was assessed during the COVID-19 pandemic and post-pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.